ClinicalTrials.gg
CompletedNCT02288845Updated Mar 10, 2017

Receptor Occupancy of ITI-007 Using Positron Emission Tomography (PET) in Patients With Stable Schizophrenia

A Phase 2 interventional study of ITI-007 in Schizophrenia, sponsored by Intra-Cellular Therapies, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2017-03-10.

Sponsored by Intra-Cellular Therapies, Inc. (part of Johnson & Johnson) · Phase 2, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing lumateperone in Schizophrenia — 3 open to participants now, 3 under way, 2 of them phase 3. lumateperone · Schizophrenia.

Enrollment
11th of 12
14 · median 66
Started
2014
with 1 other
Phase 2
3 of 12
none open now
Registered
2nd of 12
by date
Lead sponsor
9 of 12
Intra-Cellular Therapies, Inc.

Among the 12 studies testing lumateperone in Schizophrenia, this one is the 11th largest by enrollment, is one of 2 that started in 2014, is one of 3 in phase 2, and was the 2nd registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

3 of the 12 studies testing lumateperone in Schizophrenia are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About lumateperone

lumateperone: first FDA approval 2019 (CAPLYTA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing lumateperone in Schizophrenia, or all of them as a file.
02

Study summary

The purpose of this study is to determine the relationship between ITI-007 dose, plasma levels and brain receptor occupancy in patients with stable schizophrenia.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with schizophrenia who are drug-free with regard to their antipsychotic medication
  • In clinical remission and free from acute exacerbation of their psychosis
  • In good health

Exclusion criteria

Exclusion Criteria:

  • medical conditions considered inappropriate for trial participation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    ITI-007

    ITI-007 formulated capsule will be administered orally once daily for up to 14 days in up to 14 subjects.

    Drug: ITI-007

Interventions

06

What researchers measure

Primary outcomes

  1. Brain Receptor Occupancy as Measured by Positron Emission Tomography

    Time frame: Up to 14 days

Secondary outcomes

  1. Safety and Tolerability as Measured by Number of Participants with Adverse Events

    Time frame: Up to 14 days

07

Study locations

1 site
  • Johns Hopkins Medical Institutions
    Baltimore, Maryland 21287, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2014, a primary completion of Jul 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2014
First posted
Nov 11, 2014
Start
Oct 2014
Primary completionActual
Jul 2015
CompletionActual
Sep 2015
Results delay requested
Mar 9, 2017
Last update
Mar 10, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02288845
Responsible party
Sponsor
First posted
Nov 11, 2014
Start date
Oct 2014
Primary completion
Jul 2015
Completion
Sep 2015
Last update
Mar 10, 2017

Study contacts

Kimberly Vanover, Ph.D.
study director · Intra-Cellular Therapies, Inc. (ITI)
Dean F. Wong, M.D., Ph.D.
principal investigator · Johns Hopkins University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lumateperone

Start the discussion